Why big pharma buys instead of builds: the innovation arms race with biotech
# Why big pharma buys instead of builds: the innovation arms race with biotech
In March 2023, Pfizer paid $43 billion to buy Seagen, a biotech that had never had a blockbuster year on its own. Pfizer didn't need Seagen's factories or its sales force. It needed one thing: a validated technology platform for antibody-drug conjugates (ADCs), a class of cancer drugs that attach chemotherapy directly to targeting antibodies. Pfizer's own labs had spent years trying to build something comparable. Buying was faster.
This is the defining power dynamic in pharma today. Big incumbents no longer try to out-invent biotech. They let biotech take the early risk, watch which bets pay off, then buy the winners.
The old model: vertically integrated discovery
Through the 1990s, large pharma companies ran their own end-to-end pipelines: target discovery, chemistry, clinical trials, manufacturing, sales. Merck and Pfizer employed armies of bench scientists. R&D productivity was high enough to justify it.
That model broke down for a few structural reasons:
Patent cliffs accelerated. When a drug's patent expires, generic competitors can copy it, and revenue can fall over 80% within a year or two. Big pharma needs a constant stream of new approvals just to replace lost revenue, and internal pipelines couldn't keep pace.
R&D costs ballooned. Estimates from the Tufts Center for the Study of Drug Development put the fully-loaded cost of bringing one new drug to market at over $2 billion (as of recent estimates, including the cost of failures). Most molecules that enter clinical trials fail.
Biotech got better at early-stage science.
Venture-backed biotechs, often spun out of university labs, became faster and more nimble at proving whether a novel mechanism works in humans. That "proof of concept" step is where most of the scientific risk lives.
Splitting the risk curve
Drug development runs through distinct phases regulated by agencies like the FDA (Food and Drug Administration, in the US) and the EMA (European Medicines Agency, in the EU):
1. Preclinical: lab and animal studies.
2. Phase 1: small human trials testing safety.
3. Phase 2: testing whether the drug actually works, in a modest patient group.
4. Phase 3: large trials required for approval.
5. Regulatory review and approval.
The biggest risk of failure sits in Phase 2, where you learn whether a promising idea actually works in the body. Biotechs, funded by venture capital, take that risk. If a molecule clears Phase 2 with strong data, its value re-rates instantly. That is the moment big pharma shows up with a checkbook.
This is a rational division of labor. Biotech investors accept binary, high-variance outcomes (a molecule either works or the company is worth near zero). Big pharma investors want steadier, diversified returns. Neither group wants to hold the other's risk profile, so acquisition is the mechanism that transfers the asset once uncertainty resolves.
Buy, license, or partner: three tools, same logic
Big pharma doesn't only acquire. There's a spectrum:
Licensing deals: the biotech keeps its independence but sells rights to a molecule, often for an upfront payment plus milestones (payments triggered by trial success or approval) and royalties on future sales. Lower cost, lower control.
Equity stakes and partnerships: pharma takes a minority position or co-develops, sharing cost and future profit.
Outright acquisition: full control, full upside, full price. Reserved for platforms or assets pharma considers strategically essential.
Merck's 2023 deal for Prometheus Biosciences ($10.8 billion) followed this logic closely: Prometheus had a promising Phase 2 drug for ulcerative colitis and Crohn's disease, immune conditions where Merck had a gap in its portfolio. Rather than license and share upside, Merck paid a full premium (over 75% above Prometheus's prior trading price, as widely reported at the time) to own the asset outright, betting the Phase 3 data would confirm the Phase 2 signal.
That bet is real risk. Buying post-Phase 2 is cheaper than building from scratch, but it isn't free of failure. Some acquired assets still fail in Phase 3 or post-approval. The arms race reduces, but does not eliminate, pharma's risk.
Who gains, who loses
This division of labor reshapes power across the chain:
Big pharma incumbents (Pfizer, Merck, Novartis, Roche, AbbVie, Johnson & Johnson) keep control over what matters most at scale: global regulatory affairs, manufacturing at volume, and sales forces that can reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → thousands of prescribers. That's where their moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.Voir la définition complète → is now, not early science.
Biotech challengers capture outsized returns if they succeed, but most don't. Venture capital funds this asset class knowing most bets go to zero and a few pay for the rest.
Venture capital and specialist biotech investors effectively become pharma's outsourced early-stage R&D department, just organized through capital markets instead of an org chart.
Contract research organizations (CROs), firms like IQVIA or Icon that run clinical trials on behalf of biotech and pharma, gain steady work regardless of who owns the molecule.
Payers and regulators don't participate in the deal-making, but they shape which assets are worth acquiring. A drug that treats a disease with poor existing treatment and a receptive reimbursement environment (in the US, driven partly by the Inflation Reduction Act's drug pricing provisions; in Europe, by national health technology assessment bodies) is a much more attractive acquisition target.
The upshot: value increasingly concentrates at two points in the chain: the biotechs that survive Phase 2, and the incumbents big enough to write nine or ten-figure checks. Everyone in between (generics makers, smaller pharma without deal capacity) is squeezed.
Vérification des acquis
1. What was Pfizer primarily acquiring when it bought Seagen, according to the lesson?
2. What is the core logic behind big pharma letting biotech take on early-stage research risk?
3. Why did the vertically integrated, end-to-end R&D model become less viable for large pharma companies over time?
CHOIX MULTIPLES
4. Select ALL correct answers about why patent cliffs pressure big pharma to acquire biotech rather than rely solely on internal pipelines.
Sélectionnez toutes les réponses correctes.
CHOIX MULTIPLES
5. Select ALL correct answers that describe why biotechs became better positioned than big pharma to handle early-stage drug discovery risk.
Sélectionnez toutes les réponses correctes.
Why this looks like an arms race, not just good deal-making
Calling it an "arms race" is deliberate. Once one major incumbent secures a promising platform (ADCs, gene therapy, GLP-1 metabolic drugs), competitors face pressure to respond, either by acquiring a rival asset or overpaying for a similar one before a competitor does.
This dynamic pushed up biotech acquisition premiums across 2023 to 2025. It also explains clustering: after Pfizer's Seagen deal validated ADCs as a category, several other majors (AbbVie, Merck, Gilead) pursued ADC-focused acquisitions or partnerships in the same window. Nobody wants to be the incumbent left without exposure to a hot mechanism when it matures.
For a live view of how this plays out, the FDA maintains public data on drug approvals, and outlets like Endpoints News track biotech deal activity in near real time; useful for anyone wanting current examples beyond this lesson.
🎬 [VIDEO: "Why Big Pharma Doesn't Discover Drugs Anymore" - https://www.youtube.com/results?search_query=why+big+pharma+doesn%27t+discover+drugs+anymore - a short explainer on the shift from in-house R&D to acquisition-driven pipelines in the pharmaceutical industry]
The limits of the strategy
Buying isn't risk-free for incumbents:
Overpaying is common. Competitive bidding wars can push acquisition prices above what later clinical or commercial results justify.
Integration risk. Biotech cultures and big pharma bureaucracies don't always merge well; key scientists sometimes leave shortly after acquisition.
Pipeline dependence. Incumbents that rely too heavily on M&A can hollow out internal discovery capability, becoming permanently dependent on external deal flow.
Key Takeaways
Big pharma increasingly lets biotech absorb early-stage scientific risk (Phase 1 and 2), then acquires or licenses the assets that prove out, rather than running that risk internally.
Pfizer-Seagen ($43 billion, 2023) and Merck-Prometheus ($10.8 billion, 2023) show the pattern: acquire a validated platform or molecule right after it clears its riskiest scientific hurdle.
Three deal structures exist on a spectrum of cost and control: licensing (cheapest, least control), partnership/equity stakes, and outright acquisition (most expensive, full control).
Power concentrates at two points in the value chain: biotechs that survive Phase 2 trials, and incumbents large enough to fund big acquisitions; smaller players without deal capacity get squeezed.
The "arms race" framing matters because one incumbent validating a technology category (like ADCs) triggers competitive follow-on deals from rivals, inflating prices industry-wide.